Updates

Fevertree Drinks - Brokers upgrade again

September 2016

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Interims have triggered another upgrade to brokers expectations, sending the shares surging towards £9. Revenues rose 70% to £40.6m while adjusted EBITDA increased 72% to £12.4m. Eps increased 83% to 8.1p while net cash rose from £7.9m to £18.6m.All regions performed well with sales rising 108% in the UK, 33% (at constant currency) in Continental Europe, 46% in USA and 73% in Rest of Wold (mainly Australia & Canada).Looking at product development there was a new bespoke embossed bottle launched in the UK, which will be rolled out internationally in H2, while it’s also launched a new aromatic flavour tonic.Shore Capital reiterates that there’s still plenty of lower hanging fr ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Sports Direct - Share buyback lifts sentiment

Tarsus - Liberum has 350p price target

Fevertree - Chairman acquires 45,000 shares (March 2024)

Fevertree Drinks - Premium tonic water firm eyes $1.2bn US mixer market (March 2019)

Fevertree (July 2017)

Fevertree - Shares break to new highs (March 2017)

Fevertree Drinks - Purveyor of premium tonic water enjoys multiple eps upgrades (August 2016)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X